ArticleMolecular medicine reports2019
Long non‑coding RNA NORAD promotes cell proliferation and glycolysis in non‑small cell lung cancer by acting as a sponge for miR‑136‑5p.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- LncRNA FOXP4-AS1 promotes glioma cell proliferation, metastasis, and glycolysis via the miR-136-5p/ADCYAP1R1 axis.Functional & integrative genomics · 2026Article
- Comprehensive landscape and future perspective of long noncoding RNAs in non-small cell lung cancer: it takes a village.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Exploration of the mechanism of NORAD activation of TGF-β1/Smad3 through miR-136-5p and promotion of tacrolimus-induced renal fibrosis.Renal failure · 2023Article
- Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention.Journal of experimental & clinical cancer research : CR · 2022Review
- Crosstalk between Long Non Coding RNAs, microRNAs and DNA Damage Repair in Prostate Cancer: New Therapeutic Opportunities?Cancers · 2022Review
- Understanding the Critical Role of Glycolysis-Related lncRNAs in Lung Adenocarcinoma Based on Three Molecular Subtypes.BioMed research international · 2022Article
- lncRNA NORAD promotes lung cancer progression by competitively binding to miR-28-3p with E2F2.Open medicine (Warsaw, Poland) · 2022Article
- Downregulation of lncRNA NEAT1 alleviates sepsis-induced acute kidney injury.Central-European journal of immunology · 2022Article
- Article
- Long non-coding RNA NORAD induces phenotypic regulation of vascular smooth muscle cells through regulating microRNA-136-5p-targeted KDM1A.Cell cycle (Georgetown, Tex.) · 2021Article
- Long non-coding RNA NORAD promotes pancreatic cancer stem cell proliferation and self-renewal by blocking microRNA-202-5p-mediated ANP32E inhibition.Journal of translational medicine · 2021Article
- LncRNA NORAD, sponging miR-363-3p, promotes invasion and EMT by upregulating PEAK1 and activating the ERK signaling pathway in NSCLC cells.Journal of bioenergetics and biomembranes · 2021Article
- MCM3AP-AS1 promotes cisplatin resistance in gastric cancer cells via the miR-138/FOXC1 axis.Oncology letters · 2021Article
- MiR-182 inhibits proliferation, migration, invasion and inflammation of endometrial stromal cells through deactivation of NF-κB signaling pathway in endometriosis.Molecular and cellular biochemistry · 2021Article
- Competing endogenous RNAs in lung cancer.Cancer biology & medicine · 2021Review
- NORAD regulates epithelial‑mesenchymal transition of non‑small cell lung cancer cells via miR‑422a.Molecular medicine reports · 2021Article
- Non-coding RNA Activated by DNA Damage: Review of Its Roles in the Carcinogenesis.Frontiers in cell and developmental biology · 2021Review
- Circ_0044516 Regulates miR-136/MAT2A Pathway to Facilitate Lung Cancer Development.Journal of immunology research · 2021Article
- Regulation of Glycolysis by Non-coding RNAs in Cancer: Switching on the Warburg Effect.Molecular therapy oncolytics · 2020Review
- Long non-coding RNA NORAD contributes to the proliferation, invasion and EMT progression of prostate cancer via the miR-30a-5p/RAB11A/WNT/β-catenin pathway.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NORAD (non‑coding RNA activated by DNA damage) is a long non‑coding RNA (lncRNA) that is upregulated and promotes cell progression in various human types of cancer; however, its function in non‑small cell lung cancer (NSCLC) remains unclear. The present study investigated the regulatory function and underlying mechanisms of NORAD in NSCLC. NORAD and miR‑136‑5p expression were assessed by reverse transcription‑quantitative polymerase chain reaction, and proliferation and glycolysis‑associated markers were also assessed. Direct miR‑136‑5p regulation by NORAD was detected using luciferase reporter assay and RNA immunoprecipitation. NORAD was highly expressed in NSCLC tissues and cell lines. NORAD overexpression increased NSCLC proliferation and glycolysis. Further investigation revealed that NORAD serves as a competing endogenous RNA for miR‑136‑5p. Gain‑ and loss‑of‑function experiments confirmed that miR‑136‑5p reversed the promoting effects of NORAD in NSCLC. Results of the present study indicate that NORAD serves as a growth‑promoting lncRNA in NSCLC by suppressing the function of miR‑136‑5p. NORAD and miR‑136‑5p interaction may provide a potential target for NSCLC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.